Commenting on further clearances, Roselabs Biosciences director Zameer Agarwal was quoted by The Hindu as saying that Roselabs is awaiting regulatory approvals from 35-40 countries.
A drug delivery system in regulated markets, PFS seeks to deliver assured sterility, safety, convenience, greater accuracy, minimal over-filling, low medical waste, and eliminate accidental needle stick injuries, he added.
At the facility, Roselabs seeks to manufacture empty glass and polymer syringes, contract manufacturing, development of any formulation in PFS, and of customised drug delivery system and marketing formulations under its own brand name.
The company has commenced production six months ago, Agarwal said.